These press releases are for business and financial media.
-
-
- Press release archive 2009
- 05 October 2009
- ONGLYZA (saxagliptin) Receives Marketing Authorisation in Europe for the Treatment of Type 2 Diabete AstraZeneca and Bristol-Myers Squibb Company announced today that the European Commission has granted marketing authorisation for ONGLYZA (saxagliptin) in the 27 countries of the European Union.
-
-
-
- Press release archive 2009
- 05 October 2009
- Study Finds That ONGLYZA (saxagliptin) When Added to Metformin was Non-Inferior to Januvia (sitagliptin) When Added to Metformin in Reducing Hemoglobin (HbA1c) in Adults with Type 2 Diabetes Mellitus Results from an 18-week phase IIIb study in adults with type 2 diabetes with inadequate glycemic control on metformin therapy alone found that the addition of treatment with ONGLYZA (saxagliptin) 5 mg per day achieved the primary objective of demonstrating non-inferiority compared to the addition of treatment with JANUVIA (sitagliptin) 100 mg per day in reducing HbA1c from baseline.
-
-
-
- Press release archive 2009
- 02 October 2009
- Dapagliflozen Study Demonstrated Significantly Improved Glycemic Control and Weight Reduction in Type 2 Diabetes Patients Inadequately Controlled with Metformin Results from a 24-week phase 3 clinical study demonstrated that the investigational drug dapagliflozin, added to metformin, demonstrated significant mean reductions in the primary endpoint, glycosylated hemoglobin level (HbA1c) and in the secondary endpoint, fasting plasma glucose (FPG) in patients with type 2 diabetes inadequately controlled with metformin alone, as compared to placebo plus metformin.
-
-
-
- Press release archive 2009
- 29 September 2009
- Seroquel XR and Seroquel Approved in Europe for Prevention of Recurrence of Bipolar Disorder AstraZeneca announced today that once-daily SEROQUEL XR (quetiapine fumarate extended-release tablets) and SEROQUEL (quetiapine fumarate) have been approved under the European Mutual Recognition Procedure for the prevention of recurrence of bipolar disorder in patients whose manic, mixed or depressive episode has responded to quetiapine treatment.
-
-
-
- Press release archive 2009
- 25 September 2009
- US Court of Appeals Affirms Summary Judgment Decision in Seroquel Patent Litigation AstraZeneca today announced that the US Court of Appeals for the Federal Circuit has affirmed the Summary Judgment decision of No Inequitable Conduct in patent litigation involving SEROQUEL (quetiapine fumarate) tablets.
-
-
-
- Press release archive 2009
- 25 September 2009
- Brilinta Reduced Cardiovascular Deaths and Heart Attacks in ACS Patients Undergoing Heart Procedures: New Data from PLATO Trial New data from the phase III PLATO study showed that BRILINTA (ticagrelor) provided greater reduction of cardiovascular (CV) events (composite of CV death, heart attack and stroke) than clopidogrel (9.02% vs. 10.65%, p=0.0025 a 16% Relative Risk Reduction) in acute coronary syndromes patients undergoing planned invasive treatment (either PCI or CABG). Patients with planned invasive procedures at randomisation accounted for more than 70% of the greater than 18,000 patients in PLATO.
-
-
-
- Press release archive 2009
- 21 September 2009
- AstraZeneca and Nektar Sign Worldwide Agreement for Nektar Drug Development Programmes to Address Opioid-Induced Constipation AstraZeneca and Nektar Therapeutics announced today that they have entered into an exclusive worldwide license agreement for two drug development programmes.
-
-
-
- Press release archive 2009
- 31 August 2009
- AstraZeneca Announces FDA Acceptance of New Drug Application for VIMOVO AstraZeneca today announced that the US Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) submitted on 30 June 2009 by its development partner, POZEN, Inc., for VIMOVO (enteric-coated naproxen/immediate release esomeprazole magnesium, formerly known as PN400) tablets.
-
-
-
- Press release archive 2009
- 30 August 2009
- Phase III Head to Head Trial Showed Ticagrelor Reduced Cardiovascular Death and Heart Attacks Over Clopidogrel in Acute Coronary Syndromes Patients AstraZeneca today announced results from the phase III head to head trial, PLATO.
-
-
-
- Press release archive 2009
- 12 August 2009
- AstraZeneca and Forest Laboratories to Co-Develop and Commercialise a Late Stage Next Generation Anti-Infective AstraZeneca and Forest Laboratories announced today they have entered into a definitive collaboration agreement to co-develop and commercialise ceftaroline in all markets outside the United States, Canada and Japan. Ceftaroline is Forest’s late stage, next generation cephalosporin being investigated for the treatment of complicated skin and skin structure infections (cSSSI) and community-acquired bacterial pneumonia (CABP).
-
Not signed in
Page tools
Share price
- London
-
26.95 GBP - New York
-
44.82 USD
- Stockholm
-
310.10 SEK
At 21-Nov-2009 08:15 GMT
Detailed share priceIntroduction to AstraZeneca
Our responsibility
We continue to communicate openly on a range of issues, including:
